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Inhibitor of differentiation 4 (ID4), a member of the helix-loop-helix family of 
transcriptional regulators has emerged as a tumor suppressor in prostate cancer (PCa). 
Recent studies have shown that Id4 is highly expressed in the normal prostate and 
decreases in prostate cancer due to epigenetic silencing. Id4 knockdown in androgen 
sensitive LNCaP cells has been shown to lead to castration resistant prostate cancer 
(CRPC) in vitro and in vivo. Id4-/- mice leads to underdeveloped prostate with PIN like 
lesions without the loss of Androgen Receptor (AR) expression. In this study we 
demonstrate that the loss of ID4 expression in PCa cell line LNCaP and DU145 may 
promote tumorigenesis by promoting stemness. 
LNCaP cells with stably silenced ID4 ((-)ID4) using retroviral based shRNA and LNCaP 
transfected with non-specific shRNA were used to perform colony forming assay and 
ii 
 
prostatosphere formation using matrigel. Expression of cancer stem cell markers was 
determined using western blotting and immunocytochemistry (ICC). FACS analysis was 
used to sort stem cells and determine the ID4 expression. Xenograft study was performed 
on SCID mice using CD133 positive LNCaP cells. 
LNCaP(-)ID4 and DU145 cells lacking ID4 showed increased holoclone as well as 
decreased paraclone formation, which are believed to be derived from stem cells and 
differentiated cells respectively, as compared to non-silencing control in the colony 
forming assay. There was also an increase in prostatosphere development in the LNCaP 
(-) ID4 cells indicating that the loss of ID4 is responsible for promoting the LNCaP cells 
towards cancer stem cells. The results were further validated via western blotting and 
ICC using known cancer stem cell markers on the holoclones and paraclones formed by 
these cells. Xenograft study showed that 10,000 cells from CD133 positive LNCaP cells 
developed tumor on SCID mice.  
This study reports for the first time that loss of ID4 increases holoclone and 
prostatosphere formation indicating that Id4 may contribute to promoting stemness in 
prostate cancer cells.  
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The basic helix-loop-helix (bHLH) proteins belong to a large family of 
transcription factors that consist of more than 200 members across species.1 The hetero or 
homo dimerizing of bHLH proteins play an essential role in regulating the transcription 
of genes that are involved in cell fate determination.2 These proteins also regulate critical 
developmental processes such as differentiation in various cell types including B and T-
lymphocytes, muscle lineages, pancreatic B cells, neurons and osteoblasts. Within the 
bHLH family are a group of four proteins that lack basic domain but have intact HLH 
domain. These four proteins known as inhibitors of DNA-binding (ID) proteins, ID1, 
ID2, ID3 and ID4 are considered as dominant negative regulators of bHLH family of 
transcription factors. Heterodimers of ID proteins with bHLH fail to bind DNA and 
prevent transcription factors to bind to the promoters through the E-box, where it 
regulates physiological homeostasis.3 
The ID proteins negatively regulate differentiation and promote proliferation; 
hence the expression of specific subsets of ID proteins is significantly increased in many 
different types of cancers.4 Whereas ID1, ID2 and ID3 are generally considered as tumor 
promoters, ID4 has now emerged as a potential tumor suppressor.3, 5 In most of the 
cancers, the expression of ID proteins (ID1-ID3) is significantly elevated with 




On the contrary, ID4 primarily acts as a tumor suppressor in most cancers as opposed to 
ID1, ID2 and ID3.7 ID4 is epigenetically silenced in many different types of cancers 
including leukemia,8 AML,9 CLL,10 ALL,11 glial neoplasia,12 squamous cell 
carcinoma,12 gastric cancer,13 pancreatic cancer,14 prostate cancer,5, 15 colorectal 
adenocarcinoma,16 malignant lymphoma,17 cholangiocarcinoma,18 esophageal,19 and 
lung20 cancers. In prostate cancer, ID4 is also epigenetically inactivated due to 
promoter hyper-methylation.8, 21 
Analysis of ID4 knockout (ID4-/-) mice model suggested that ID4 is required for 
expansion of the proliferative zone in developing brain cortex and hippocampus by 
proliferation of neural stem cells through normal G1-S transition.22 Also ID4 promotes 
mammary gland development by suppressing p38MAPK activity.23 Above evidence 
suggests that loss of ID4 can maintain stemness in developing organs. No studies have 
reported the relationship between prostate, prostate stem cells and ID4 expression. 
Studies have shown that the response of prostate cancer after androgen ablation therapy, 
subsequent recurrences, and progression is due to resident prostate cancer stem cells in 
the tumor, which are resistant to androgen ablation therapy.24 Therefore, the mechanism 
involved in progression or maintaineance of cancer stem cell is a good platform to find a 
definitive treatment for cancer. Our studies suggest that loss of ID4 maintain prostate  
stem cell population. Therefore, understanding the mechanism by which loss of ID4 
maintains stem cells in prostate cancer may lead to the development of therapeutic 




Multiple cellular transcriptional regulatory mechanisms are involved to maintain 
cellular stemness. Specifically, OCT4, NANOG, and SOX2 transcription factors play 
major roles in maintaining stemness.25 SOX2 heterodimerizes with OCT4 and regulates 
several genes that demonstrate autologous feedback and control reciprocal transcription 
in a regulatory circuit.26 Many other factors, for example sall4, Dax1, Tbx3, also play a 
role in maintaining stemness26 via protein-protein interaction. Many of the above genes 
are also targets of NANOG and OCT4 that indicate the transcription network might 
have a feedback mechanism. Early embryonic stem cells express many proteins in 
common with cancer stem cells, especially OCT4, NANOG, and SOX227 although the 
precise underlying mechanisms are poorly understood. One theory suggests that 
arginine methylation by protein arginine methyl transferase 1 (PRMT1) on FOXO1 
molecule can act as a regulator for activation of stemness maintaining transcription 
factors.28  
Usually within same species, stem cells and somatic cells contain identical 
genomic DNA. The epigenetic regulation mainly influences the differentiation potential 
and pluripotency in stem cells. Here chromatin is subjected to various forms of 
epigenetic regulation that modulate the transcriptional activity in specific genomic 
regions, including chromatin remodeling, histone modifications, histone variants and 
DNA methylation. For example, trimethylation of lysine 9 and lysine 27 of histone 3 
(H3K9 and H3K27) correlate with inactive regions of chromatin, whereas H3K4 
trimethylation, and acetylation of H3 and H4 are associated with active transcription,29 




demonstrated that ID4 promoter methylation is initiated by Enhancer of Zeste Homolog 
2 (EZH2) dependent H3K27Me3 in DU145 and C81 prostate cancer cell lines compared 
to ID4 expressing LNCaP cell line.15 
Loss of ID4 in LNCaP cells promotes high tumorigenic ability in xenograft 
models.30 ID4 -/- studies show attenuated prostate development and hyperplasia with 
PIN like lesions.31 These results suggest that ID4 has a potential role in blocking the 
development of prostate cancer. We believe that Protein methyl Transferase1 (PRMT1) 
may play a major role in the regulation of ID4 expression at epigenetic level. Moreover, 
PRMT1 promotes FOXO1 post translational methylation and retains FOXO1 in the 
nucleus which in turn promotes cancer stemness. I, therefore, hypothesize that loss of 
ID4 promotes prostate cancer by maintaining stemness. This hypothesis will be 
investigated through the following specific aims: 
1. Investigate whether ID4 selectively regulates the colony and sphere formation ability 
in prostate cancer cells. 
2. Investigate the expression of stem cell markers in prostate cancer cell lines, 
xenografts and ID4 knockout mice models.  









2.1 Prostate Gland 
The prostate is a small gland, about the shape and size of a walnut, in men that is 
part of the reproductive system. The prostate resides below the bladder and in front of the 
rectum. It surrounds part of the urethra, the tube that carries urine from the bladder.32 The 
prostate helps make semen, which carries sperm from the testicles when a man ejaculates. 
Above the prostate and behind the bladder are two seminal vesicles which are glands that 
make a fluid that is a part of semen. 
The male gonad differentiates embryonically under the influence of the Y 
chromosome. Later, under the influence, the gonad-derived fetal testosterone acting 
through androgen receptors, a region of the urogenital sinus (UGS) mesenchyme 
differentiates to form the primordial prostate buds. After birth, the prostate keeps growing 
and reaches nearly full size during puberty. 





zone, (b) the transitional zone and (c) the central zone. The peripheral zone, which is 
approximately 70% of the prostate, is the most common origin of carcinoma,33 chronic 
prostatitis,33 and post-inflammatory atrophy.33 The central zone covers 25% of the 
prostate gland. It is cone-shaped and is located at the base of the prostate adjacent to the 
seminal vesicles. Also, central zone surrounds the ejaculatory ducts that secrete fluid that 
helps create semen. The transition zone makes up to 5% volume of the gland and 
surrounds the urethra. The prostate gland is enclosed by a fibrous tissue layer and is 
named as the prostate capsule. Commonly, this capsule is destructed when prostate 
cancer spreads out of the gland and into surrounding tissues and organs.  
 
                    A                                                                        B 
 
     







                
Figure 1.  (A)  General overview of the prostate gland. 
(B) Anatomy of the prostate gland. The three histologically distinct zones are shown: the central 
zone, the transitional zone, and the peripheral zone. (C) A schematic view of the different stages of 
prostate cancer. 
 
2.2 Prostate Cancer Incidence 
Prostate cancer is the second leading cause of cancer deaths in men.34 In the year 
2015 there were about 220,800 new cases of prostate cancer and almost 27,540 deaths are 
in the United States.34 From all the cancer deaths, prostate cancer deaths account for 
approximately 5.1 percent with 15.3 percent of men who will be diagnosed with prostate 
cancer at some point during their lifetime. About 6 out of 10 cases are diagnosed in men 
aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is 
about 66 years.35 More than 2.9 million men, who have been diagnosed with prostate 







2.2.1 Risk Factors 
Unlike other diseases and infections, most cancers do not have a single cause. 
They initiate due to the interaction of multiple factors that range from genetic 
characteristics to personal lifestyle. 
Only a few factors have been conclusively established as risk factors for prostate 
cancer, and none of them are readily modifiable aspects of a man’s lifestyle. Increasing 
age is one of the most well established risk factors for prostate cancer. The risk of 
prostate cancer begins to increase in the late forties, and it continues to increase with age. 
More than 70% of all prostate cancers are diagnosed in men over the age of 65. African 
American men have one of the highest prostate cancer rates in the world. They are 69% 
more likely than white American men to be diagnosed with prostate cancer, and they are 
more than twice as likely to die from it. 
Having a family history of prostate cancer in close male relatives is also a major 
risk factor. This risk factor may reflect a combination of inherited characteristics and 
common lifestyles shared by family members. It is believed that approximately 9% of all 
prostate cancer cases result from genetic mutations and as many as half of all prostate 
cancer cases in younger men may result from inherited conditions.37 Normal growth and 
function of the prostate gland is regulated by male sex hormones (androgens). It is 
believed that androgens (testosterone) and androgen receptors may increase the risk of 
prostate cancer.37 Differences in androgen levels may explain the variation in prostate 
cancer rates among ethnic groups. For example, several studies have shown that androgen 




groups, and this may partially explain the high susceptibility of African-American men to 
prostate cancer. Effects on androgens might also be a mechanism by which some lifestyle 
factors could influence prostate cancer risk, such as, changes in dietary habits may lead to 
changes in androgen levels and thus perhaps to changes in prostate cancer risk. 
 
2.2.2 PIN Lesions of Prostate Gland 
Histopathological analysis of prostate cancer tissue shows a specific type of lesion 
that is believed to represent the primary precursor of human prostate cancer, which is 
known as Prostate Intraepithelial Neoplasia (PIN).38 PIN lesion can be classified into four 
common types based on their microscopic appearance: tufting, micropapillary, cribiform, 
and flat. PIN is recognized as a continuum between low-grade and high-grade forms, 
with high-grade PIN thought to represent the immediate precursor of early invasive 
carcinoma. 
According to the clinical evidence, high-grade PIN (HGPIN) is implicated as a 
pre-neoplastic lesion in humans. Initially, PIN lesions are mainly found in the peripheral 
zone, in proximity to invasive carcinoma.38 Gradually, the appearance of HGPIN lesions 
generally precedes the appearance of carcinoma by at least 10 years. 
Allelic imbalance analysis has shown that PIN lesions are multifocal, as is the 
case for carcinoma; moreover, the chromosomal abnormalities found in PIN resemble 
those found in early invasive carcinoma, although they are less prevalent. Also, the 
architectural and cytological features of PIN closely resemble those of invasive 




carcinoma can be differentiated based on the markers with reduced expression of the cell 
adhesion protein E-cadherin and increased cytoskeletal component vimentin. On the 
other hand, PIN differs from invasive carcinoma in having an intact basement membrane, 
that does not invade the stroma.39 Furthermore, PIN lesions do not produce high levels of 
PSA. Therefore, PIN lesions can only be detected in biopsy samples, and not by serum 
testing. 
 
2.2.3 Diagnosis and Treatments 
The Prostate specific antigen (PSA) blood test and Digital Rectal Examination 
(DRE) can be used to detect the presence of prostate cancer when no symptoms are 
present. They can help catch the disease at an early stage when treatment is thought to be 
more effective and potentially has fewer side effects. During a digital rectal examination, 
finding any irregularities in size, shape, and texture in the prostate is suggestive of 
prostate cancer. In PSA test, the level of PSA, a protein produced by the prostate, is 
measured. PSA levels less than 4 ng/mL are usually considered “normal,” results over 10 
ng/ mL are usually considered “high,” and results between 4 and 10 ng/mL are usually 
considered “intermediate.” Some men with prostate cancer can have low levels of PSA. 
Also, high PSA levels can be seen following certain medical procedures in the presence 
of infection or the non-cancerous overgrowth of the prostate known as benign prostatic 
hyperplasia (BPH). The American Urological Association recommends that both the PSA 
and DRE should be offered annually, beginning at age 40, for men who have at least a 




strong family history of one or more first degree relatives diagnosed at an early age, are 
encouraged to also begin testing at age 40. 
 
2.2.4 Making the Diagnosis and Staging the Disease 
Although the PSA and DRE tests cannot diagnose prostate cancer, they can guide 
the need for a biopsy to examine the prostate cells and determine whether they are 
cancerous. If prostate cancer is suspected, a biopsy will be performed. During a biopsy, 
needles are inserted into the prostate to take small samples of tissue. If prostate cancer is 
found during the histological examination, the pathologist assigns a Gleason score, on a 
scale from 2–10. 
Normally, cancers with lower Gleason scores (2–4) tend be less aggressive while 
cancers with higher Gleason scores (7–10) tend to be more aggressive; cancers with 
intermediate Gleason scores (5–6) fall somewhere in the middle. Staging determines the 
extent of prostate cancer and provides an idea of how the cancer should be treated. 
Localized prostate cancer means that the cancer is confined within the prostate. Locally 
advanced prostate cancer means that most of the cancer is confined within the prostate, 
even though some has started to escape to the immediate surrounding tissues. In 
metastatic disease, prostate cancer is growing outside the prostate and its immediate 
environs, possibly in the lymph nodes and more distant organs. 
2.2.5 Treatment Options 
Outcome of the treatment depends on multi team approach. Consultation with all 




medical oncologist—will offer the most comprehensive assessment of the available 
treatments and expected outcomes. Persons diagnosed with localized or locally advanced 
prostate cancer have three major treatment options, active surveillance, surgery, and 
radiation. Choosing the best treatment for localized or locally advanced prostate cancer is 
generally based on the age, the stage and grade of the cancer, the general health, and the 
evaluation of the risks and benefits of each therapy option. 
A radical prostatectomy is the surgical removal of the entire prostate gland plus 
some surrounding tissue. The procedure can produce significant side effects that might 
affect the quality of life, including erectile dysfunction and urinary incontinence.  
Radiation involves the killing of cancer cells and surrounding tissues with directed 
radioactive exposure. With external beam radiation, high-intensity beams of radiation are 
directed at the target area; with brachytherapy, tiny radioactive metal seeds or pellets are 
surgically inserted into the prostate. Hormone therapy is often given in conjunction with 
radiation, either before, during, or after treatment. Although high doses of radiation are 
needed to kill prostate cancer cells, higher doses can also increase the rate of side effects 
such as urinary problems, erectile dysfunction, and rectal bleeding. Improvements in 
technology have allowed for very precise targeting of radiation to enable skilled and 
experienced radiation oncologists to deliver higher doses to more focused areas while 
minimizing side effects 
2.3 Mechanisms of Prostate Cancer Initiation 
Chromosomal alterations are commonly observed in prostate cancer; therefore, 




the stages of prostate cancer progression. Losses of allelic patterns reflect the reduction or 
loss-of-function of putative tumor suppressor genes in prostate cancer. In particular, 
losses of heterozygosity at chromosomes 8p, 10q, 13q, and 17p are frequent events, and 
losses of 6q, 7q, 16q, and 18q have also been reported, although they are not as well 
characterized (Figure 2).40 
 
           Figure 2. Pathways for Human Prostate Cancer Progression. 
Although, allelic loss is responsible for prostate carcinogenesis, there is no single 
candidate tumor suppressor gene that has been definitively assigned a role in cancer 
progression. Several reasonable candidate genes (e.g., RB, p53, PTEN, NKX3.1) have 
been implicated, based on their localization to regions of allelic loss and their functional 
properties, but none of these have been shown to be mutated in a large percentage of 
prostate cancer specimens, such as mechanism other than a coding region mutation, 
including promoter methylation or mutations within regulatory sequences that may affect 




Chromosomal abnormality detected using FISH shows loss of a specific region on 
chromosome 8p in 80% prostate tumors. The 8p1-21 locus represents the NKX3.1 gene 
and loss of this region is seen in prostate cancer. Occurrence of PIN lesions in NKX3.1-/-  
mice prostate supports the role of NKX3.1 in prostate cancer.41 Hence, NKX3.1 is likely 
to represent a regulatory gene whose loss is involved in prostate cancer initiation. 
Tumor suppressor PTEN/MMAC1 maps to 10p23. Loss of PTEN leads to 
occurrence of prostate carcinoma and other carcinomas including glioblastoma, breast 
and endometrial carcinoma. PTEN encodes a lipid phosphatase whose main substrate is 
PIP3. Loss of PTEN activity leads to activation of PKB/AKT kinase pathway, which is 
responsible for cellular differentiation and decrease sensitivity to cell death.42 
Inhibitor of differentiation 4 (ID4) is a dominant – negative –loop –helix protein 
belongs to the basic helix –loop-helix family transcription factor has been recognized as a 
tumor suppressor based on the evidence that it is epigenetically silenced in many cancers. 
According to our studies, loss of ID4 in LNCaP cells demonstrates high tumorigenic 
ability in xenograft Studies ID4-/- mice studies show that loss of ID4 attenuate prostate 
development and promotes hyperplasia with PIN like lesions suggesting ID4 has 
potential role in development of prostate cancer.  
Large scale genome wide association studies of prostate cancer and other 
epithelial cancers show that chromosome locus at 8q24 region is amplified. This region 
represents the MYC oncogene and studies showed that MYC protein is upregulated in 
many PIN lesions and majority of carcinomas. Likewise many tumor suppressor  genes 




2.4 Androgen and Androgen Receptor in Prostate Cancer 
Androgen and androgen receptor (AR) activity also play a major role in initiation 
and progression of prostate cancer. The mechanism of action on AR in prostate cancer is 
complicated, as some develop/get recurrence of prostate cancer even after androgen 
deprivation therapy.43 Androgen is  independent stage of prostate cancer shows increase 
the level of PSA, indicating there are many mechanisms that activate AR, such as AR 
amplification/overexpression, gain of faction AR mutations (mostly in ligand binding 
domain), intracrine androgen production, over expression of androgen cofactors, ligand 
independent AR activation by cytokines or growth factors, and constitutively active 
splice variants of AR.44 
Castration resistant prostate cancer produces intra-tumoral androgens as a result 
of de novo steroidogenesis,  even though this mechanism of steroidogenesis is not 
established and  is suggested that enzymes such as CYP17A1 may be involved.45 
However in CRPC, AR will be in most case   constitutively active and studying this 
mechanism would be important in treating prostate cancer. 
2.5 Stem Cells 
Stem cells are small subsets of cells found in all multicellular organisms that can 
either mitotically divide to self-renew and produce more stem cells or differentiate into 
mature cells in a particular tissue. Unlike somatic cells, stem cells can self-renew for a 
long time. There are mainly two types of stem cells depending on their occurrence: 
embryonic stem cells and adult stem cells. Embryonic stem cells (ESC) are obtained from 




of the body while the adult or somatic stem cells are restricted to a particular adult 
tissue.46 Adult stem cells, also known as somatic stem cells or tissue-specific stem cells 
are present in all kinds of tissues like, blood, bone marrow, brain, and fat, occupying a 
small portion in the adult tissue. 
  According to behavior, these stem cells can be divided into two different stem cell 
types called general stem cells and cancer stem cells. 
2.5.1 Features of Stem Cells 
1 Growth behavior of stem cells - unlimited proliferative potential (common feature for 
stem cells and cancer cells)  
Although stem cells and cancer cells have a key feature called “Unlimited 
proliferation potential” as a common trait, a cell must acquire several key characteristics 
in order to become cancerous.47 Features that make a cell cancerous are unlimited 
proliferation (even in the absence of extracellular signals), resistance to apoptosis, 
evasion of anti-growth signals and immune destruction, and increased cellular motility, 
which give the added advantages to the cancer cells to metastasize.48 
However, stem cells are not involved in biologically destructive phenomenon like 
immune destruction. Some of the stem cells, like mesenchymal stem cells, have increased 
cellular motility, and they can also assist other cell types to have an enhanced cellular 
motility.49 Furthermore, unlike the cancer cell motility behavior, the natural purpose of 
stem cell motility is secondary homing to contribute to cell and tissue regeneration. So, 
stem cells and cancer cells have many of the features in common, but the purpose of such 




2  Potency 
Differentiation potential of the stem cell is called potency and five potency types 
can be identified in the body. 
1. Totipotency is the ability of a single cell to divide and produce all of the differentiated 
cells in an organism. In the spectrum of cell potency, totipotency represents the cell with 
the greatest differentiation potential. 
2. Pluripotency refers to a stem cell that has the potential to differentiate into any of the 
three germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), 
mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous 
system).50 
3. Multipotency describes progenitor cells, which have the gene activation potential to 
differentiate into multiple, but limited cell types. For example, a multipotent blood stem 
cell is a hematopoietic cell and this cell type can differentiate itself into several types of 
blood cell types like lymphocytes, monocytes, neutrophils.51 
4. Oligopotency is the ability of progenitor cells to differentiate into a few cell types. 
5. The unipotent cell is the concept that one stem cell has the capacity to differentiate into 
only one cell type. Although general stem cells have a different type of potency, all 
cancer stem cells have pluripotency and can be differentiated into well-differentiated, 







2.5.2 Molecular Mechanism that Maintain Stemness 
OCT4, NANOG, and SOX2 transcription factors play a major role in maintaining 
stemness. SOX2 heterodimerize with OCT4 and regulate several genes, demonstrating 
autologous feedback and control reciprocal transcription in a regulatory circuit.52 
Apart from above transcription factors, many other factors (proteins) such as, sall4, Dax1, 
Tbx3 play a role in maintaining stemness, via protein-protein interaction. Many of the 
genes encoding proteins in the interaction network are targets of NANOG and OCT4, 
indicating that the transcription network might have a feedback mechanism through the 
protein interaction network. 
Usually given same species, stem cells and somatic cells contain identical 
genomic DNA. The epigenetic regulation mainly influences the differentiation potential 
and pluripotency in stem cells. Here chromatin is subjected to various forms of epigenetic 
regulation that modulate the transcriptional activity in specific genomic regions, 
including chromatin remodeling, histone modifications, histone variants, and DNA 
methylation. For example, trimethylation of lysine 9 and lysine 27 of histone 3 (H3K9 
and H3K27) correlate with inactive regions of chromatin, whereas H3K4 trimethylation 
and acetylation of H3 and H4 are associated with active transcription53 and DNA 
methylation generally represses gene expression. 
 Recent studies demonstrated that micro RNA is also significant in maintaining 






2.5.3 Roles of Stem Cells in a Biological System 
Although stem cells occupy a small percentage of an adult tissue, they have 
profound biological significance. The basic biological significance of adult stem cells is 
to act as a reservoir of progenitor cells which can in turn act as a repair system, primarily 
for that particular tissue or other tissues of that particular germline. It is also likely that in 
the post-natal period of mammalian development a very small portion of pluripotent stem 
cells reside in all the tissues in the form of very small embryonic/ epiblast-like stem cell, 
in addition to, the uni/multipotent adult or somatic stem cells. 
It was thought that stem cells residing in the bone marrow could give rise only to 
blood cells. However, emerging evidence suggests that adult stem cells may be more 
versatile than previously thought and able to create unrelated types of cells, either from 
the same or different germ layer. For instance, bone marrow stem cells may be able to 
create muscle cells, beta islet cells etc.51 
2.5.4 Cancer Stem Cell Theory 
It has been suggested that CRPC recurrence takes place because of residing 
prostate cancer stem cells in the tumor without undergoing apoptosis/die during androgen 
ablation.42 According to the cancer stem cell theory, the behavioral pattern and 
heterogeneity of cancers can be explained, and the study of cancer stem cell is a good 
platform to find a definitive treatment for cancer. 
In 1979 John Dick and co-workers showed that leukemic stem cells which have 
CD43 (+) and CD38 (-) surface markers can be transplanted to SCID mice in linear 




formation ability.43 In 2003, Ul Hajj and co-workers performed a similar kind of 
experiment on solid tumor (Breast) to demonstrate the existence of cancer stem cells.44 
Also, a cancer stem cell study on DU145 cells has shown that even 10,000 cancer stem 
cells were enough for the development of prostate cancer in xenograft within 40 days.46 It 
is believed that tumors have a hierarchy of cells headed by cancer stem cells which can 
self-renew and differentiate to different stages cell types in cancer (heterogeneity). 
2.5.5 Features of Cancer Cells and Cancer Stem Cells 
Cancer cells are cells having unlimited proliferation potential divide at an 
unregulated fast pace leading to failure of regulation of tissue growth. In order to 
transform a normal cell into a cancer cell, the genes which regulate cell growth and 
differentiation must be altered. The development of cancer is a complex multistep 
process that requires the accumulation of mutations resulting in a cell acquiring the 
essential hallmarks of cancer: evasion of apoptosis, self-sufficiency in growth signals, 
insensitivity to antigrowth signals, invasive and metastatic abilities, limitless replicative 
potential, and sustained angiogenesis.  
Given that normal adult stem cells already exhibit limitless replicative potential, it 
is hypothesized that transformed stems cells may be the cells of origin for many 
cancers,53  and hence, can also be termed as cancer stem cells (CSCs). CSCs, also known 
as cancer initiating cells, are defined as the fraction of cells within a tumor that are long-
lived, possess the potential to proliferate indefinitely, and can generate all heterogeneous 
lineages of the original tumor in xenograft models46-47. CSCs are expected to utilize 




activity, specific signaling pathway activity, and regulation of cell cycling characteristics 
with aberrant regulation.2b, 48  
One of the major characteristic features of CSC is that the ability to form a sphere 
and colonies. CSC sphere can be developed in matri-gel and even 500 cells from CSC 
sphere have the ability to develop cancer on xenograft.49 Apart from the sphere, 
researchers have shown that stem cells have the ability to form colonies in normal culture 
media. There are different morphological colonies that can be seen under the microscope. 
Colonies that are large and round have a smooth perimeter and mostly contain small 
cells, which can be passaged many times and has significant growth potential called 
“Holoclone.” Transplantation experiments have demonstrated the ability of these clones 
to form tumors with a very small amount of cells suggesting high stemness. Also, they 
express other characteristic features of stem cells.49 
Aborted colonies that are small, have an irregular shape and contain large 
flattened differentiated square like cells called “paraclone.” These colonies cannot be 
passaged and are formed by cells with restricted growth potential.47 Mixed colonies 
usually have jagged perimeter and contain intermingled areas of small and large 
differentiated cells. These colonies can only be passaged a limited number of times and 
are formed by cells with limited potentials. These colonies are called “Meroclone.”47 
Since cancer stem cells are the small aggressive population within the entire 
population of cancer cells, it is important to identify and target such population of CSC 
for successful cancer therapies, thereby avoiding a cancer relapse. CSCs of various 




CD44, CD24 and CD133, Thy-1, Sca-1.54 Such marker proteins have a great potential to 
be harnessed as biomarkers for CSCs. Also, some of the proteins are commonly shared 
amongst various cancers/ CSCs. Furthermore, these marker molecules are also known to 
play roles in various biological processes, in addition to, their respective roles in cancer 
stem cells.  
The hierarchical model assumes that cancer stem cells (CSCs) represent a 
biologically distinct subset within the total malignant cell population. It is the only model 
that is relevant to the designation of malignant tumor-propagating cells as CSCs, 
although it does not require that CSCs are functionally or genetically homogeneous. 
According to this model, a pool of CSCs can only be maintained by cells that have both 
CSC potential and, by definition, the ability to give rise to progeny with self-limited 
proliferative capacity. This model precludes the concept of reversibility between 
intrinsically determined states of unrestricted and limited proliferative potential. 
However, it accommodates the possibility that CSCs, like their normal counterparts, may 
retain responsiveness to external cues to elicit their intrinsically determined potentialities 
for survival, growth, and differentiation, irrespective of how perturbed the process of 
differentiation. The clinical implication from this model is that the elimination of all 
CSCs will inevitably terminate the growth of the tumor and that failure to do so leaves 
open the possibility of relapse. 
By contrast, the stochastic model assumes that every cell within a tumor has the 
same potential to act as a CSC and that their variable activities are at least partially 




are not totally determined by the environment in which the cells are found. 
Experimentally, the stochastic model can mimic a hierarchy in which the CSCs are rare 
and produce cells with diminished proliferative capacity because only a proportion of 
cells at any given moment exhibits CSC activity. 
2.5.6 Mechanism Involving in Maintaining Cancer Stem Cells 
  Oncogenic cellular reprogramming promotes the acquisition of uncontrolled self-
renewal of cancer cells with the expressing of cancer stem cell genes. In reprogramming 
process, epigenetic mechanisms integrate the effect of cell-intrinsic and cell-extrinsic 
changes and establish intra-tumoral heterogeneity, either promoting or inhibiting the CSC 
state.55  Epigenetic mechanisms involving DNA methylation and chromatin play a 
diverse role in cancer by promoting, sustaining, enhancing, or inhibiting malignant 
phenotypes at various stages of the disease. Research over the past decade has revealed 
that both cell-intrinsic (i.e., mutations) and cell-extrinsic (i.e., environmental cues) 
mechanisms modulate the epigenome of cancer cells, and their combined effect 
determines which cells preserve the self-renewal capacity acquired during tumorigenesis. 
These cells referred to as cancer stem cells (CSCs) or leukemic stem cells (LSCs) are 
those responsible for driving long-term cancer growth and disease progression.56 
CSCs/LSCs evolve over time as a consequence of genetic heterogeneity that generates 
self-renewing subclones with diverse fitness, and environmental changes that modulate 
their phenotype. 




In leukemias, cancers are maintained by LSCs. Numerous studies have identified 
mutated epigenetic regulators that favor the acquisition of uncontrolled self-renewal 
ability and initiate the disease. A prominent example is offered by mixed lineage 
leukemia (MLL)-associated leukemia, which is characterized by chromosomal 
rearrangements involving the KMT2A/MLL gene. KMT2A/MLL encodes a histone 
methyltransferase that orchestrates several essential cellular processes through 
modification of chromatin, mainly regulating accessibility to enhancer regions. 
Oncogenic MLL fusion proteins created by translocations induce LSC formation in acute 
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Importantly, MLL 
fusion proteins can initiate the oncogenic process, both, in hematopoietic stem cells and 
in short-lived progenitors, suggesting that they are able to reprogram committed cells and 
actively confer de novo self-renewal capacity. 
The primary mechanism leading to oncogenesis induced by the K27M mutation is 
inhibition of the Polycomb repressive complex 2 (PRC2), which results in a genome-
wide reduction in the repressive histone H3 trimethylated lysine 27 (H3K27me3) mark 
and re-establishment of an earlier developmental program in precursor cells and 
consequent acquisition of oncogenic self-renewal ability. 
Proteins involved in the establishment and maintenance of DNA methylation have 
also been identified as drivers of CSC formation. CpG dinucleotides methylation 
(epigenetic) depends on the action of DNA methyltransferases (DNMT1, DNMT3A, and 




methylcytosine to 5-hydroxymethylcytosine is done by methylcytosine dioxygenases 
(TET1 and TET2), which initiate a demethylation process.  
Both processes histone methylation and DNA methylation play a major role in a 
reprograming cell into cancer stem cells. 
2.5.7 Cancer Stem Cells Therapy 
Conventional cancer therapies like chemo and radiotherapy are often unable to 
kill CSC. This will ultimately affect the patient by recurring cancer or via toxicity to 
healthy tissues. CSCs therapy indicates cancer therapy by targeting the CSCs population 
using various methods. Currently, CSCs therapy is gaining much attention from the 
researchers because of its ability to target CSCs, that are responsible for initiation, 
progression, and metastasis of cancer.57 Therefore, CSCs therapy is becoming an 
important focus of cancer research aiming to complete elimination of malignancies.  
To target CSCs, various approaches can be taken. 
1. Signaling pathways: Common signaling pathways shared between normal stem 
cells and CSCs like Hedgehog (Hh), Notch, Wnt/b-catenin, high mobility group 
AT-hook 2 (HMGA2), Bcl-2, Bmi-1, and etc. undergo aberrant activation or 
dysregulation to give rise to CSCs 58. Targeting these signaling pathways can be 
as a treatment method. 
2. Targeting CSC markers-Certain cytotoxic drugs, short hairpin RNA molecules, 
antibodies, which primarily target the cell surface markers of CSCs, can prove to 




3. Targeting drug detoxifying enzymes and drug efflux pumps present in CSCs. For 
example, drugs against detoxifying enzymes like ALDH1 as described previous. 
2.6. Inhibitor of DNA Binding (ID) Proteins: 
ID proteins are typically expressed in highly proliferating cells and their 
expression levels decrease in differentiated cells. IDs are known to be positive regulators 
of cell growth and negative regulators of cell differentiation. ID proteins play key roles in 
the regulation of lineage commitment, cell fates decisions,59 and also have a role in cell 
signaling, DNA damage control, and apoptosis. They also act in the timing of 
differentiation during neurogenesis, lymphopoiesis, and neo-vascularisation 
(angiogenesis) and are essential for embryogenesis and cell cycle progression.59-60 Helix 
Loop Helix (HLH) proteins that positively regulate sets of genes during cell fate 
determination and cell differentiation, possess a region high in basic amino acids adjacent 
to HLH domain, that facilitates binding to DNA containing the canonical ‘E box’ 
recognition sequence, CANNTG and ‘N box’ sequence, CACNAG61 or Ets recognition 
sequence, and GGAA/T present in the promoter regions of regulated proteins,62 and thus, 
forms a large superfamily of transcription factors that regulate tissue-specific 
transcription.61 However, a distinct subfamily of HLH proteins, the ID proteins, lacks 
these basic DNA-binding region and instead function solely by dimerization with other 
transcriptional regulators. Principally, those of the bHLH type and such ID-bHLH 
heterodimers are unable to bind to DNA, and hence ID proteins act as dominant negative 




as E2A, E2-2, or HEB, and also with factors such as RB (retinoblastoma) family 
members that have a role in cell cycle.6b 
The ID family consists of four isoforms: ID1, ID2, ID3, and ID4 60structurally; 
the core HLH domain between ID and bHLH proteins is highly conserved. The 
interference of ID proteins with the key regulatory bHLH proteins is therefore an 
important interaction for proliferation and differentiation. In human, the ID1,ID2, ID3, 
and ID4 genes map to same chromosome at positions 20q11(75), 2p25 (76), 1p36 (78), 
and 6p21.3-22, 61 where all of them share considerable homology to one another and 
seem to have derived from a common ancestral gene.60 
Widespread expression of ID1, ID2, and ID3 genes was demonstrated throughout 
from early gestation to birth during mouse development, with considerable overlap of 
ID1 and ID3, and distinct ID4 expression limited to the nervous system.61 Deletion of 
ID1 gene in mice, failed to generate phenotype, and ID2 null mice possessed defects in 
immunity due to lack of lymph nodes, while mice null for ID3 had defects in B cell 
proliferation and humoral immunity.4 Mice null for both ID1 and ID3 possessed 
embryonic lethality with aberrant neuronal differentiation and angiogenesis.63 ID1, ID2, 
and ID3 which are identified as mitogen responsive61 are further implicated in cell cycle 
progression when antisense ID constructs are introduced into serum stimulated NIH3T3 
cells.61 ID1had shown to inhibit, E-protein and ETS mediated activation of the cdk 
inhibitor p16/INK4a.63 ID2 and ID3 have been shown to get phosphorylated in the late 
G1 stage of cell cycle by cyclin dependent kinase 2 (CDK2),64 and ID2 by interacting via 




growth inhibition.  ID proteins induce apoptosis in accordance with their expression. 
Expression of ID1 in dense mammary epithelial cell cultures, 82 ID3 in B-lymphocytes 64b 
and ID4 in astrocyte-derived cell line induces apoptosis. 
In general, the expression of Id proteins is high in proliferating cells as ID 
proteins (ID1-ID3) promote cell proliferation65 and expression is down regulated during 
differentiation .105  ID1, ID2, and ID3 are upregulated are in pancreatic cancers66 , 
colorectal cancers67, astrocytic tumors67, and squamous cell carcinomas of head and 
neck.62  ID4 expression is reported to be decreased in many cancers68 due to promoter 
hyper methylation66 except in testicular seminomas where all ID genes are upregulated.68 
As key regulators of cell cycle and differentiation, Id proteins have shown a vast 
regulatory function across diverse cellular functions including cell cycle, apoptosis, 
senescence and tumorigenesis in cancer.62  
2.6.1 Inhibitor of DNA Binding 4 (ID4) Proteins: 
ID4 proteins are dominant negative regulators of basic helix-loop-helix 
transcription factors. The human ID4 has two coding exons and produces a protein 
predicted to be approximately 17kDa. In mice, ID4 mRNA is expressed predominately in 
developing and mature neuronal tissue, bladder and bone marrow. 
ID4 expression in prostate cancer is associated with an increased risk of 
metastasis.69 A more recent study (Carey et al) found ID4 promoter methylation in 
prostate cancer. Ectopic expression of ID4 results in cell cycle arrest. ID4 promoter 
methylation and loss of expression have also been documented in colorectal 




protein down-regulates BRCA1 expression71 and its expression is inversely correlated 
with estrogen receptor expression in breast cancer malignancies.16  
The sub-cellular localization of the ID proteins is considered nuclear, but differs 
with cell type, differentiation stage and post translational modification.72 In normal rat 
breast tissue ID4 sub-cellular localization changes with the differentiation stage of the 
epithelia, with more nuclear staining in proliferating epithelia and in all other stages it is 
either mostly cytoplasmic or very weakly expressed.73 In prostate cancer cell lines ID4 
protein has a different effect on the cell cycle. ID4 ectopically over-expressed in prostate 
cancer cell lines induced S phase arrest and apoptosis that was attributed to ID4 up-
regulating the expression of E2A which in turn increased the levels of p21 and p27 
expression. ID4 has also been demonstrated to increase cyclin E levels in cdkn2a -/- 
astrocytes, which drives their proliferation.74 In neural precursors, ID4 protein is required 
for the G1 to S phase transition in the cell cycle.22 
ID4 plays an important role in the nervous system and particularly in 
oligodendrocyte differentiation by directly binding to OLIG1 and OLIG2 bHLH proteins 
responsible for neural progenitor cells.22, 75  The specific nature of ID4 protein expression 
in cancer has not been clarified, however, studies support that ID4 has both pro-tumor 
and anti-tumor activity. Epigenetic silencing of ID4 in leukemia76, breast 77, colorectal22 , 
mouse and human chronic lymphocytic leukemia (CLL)75, and gastric cancer8  tend to 
support its antitumor activity. It is highly expressed in bladder and rat mammary gland 
carcinomas suggesting that it may have pro-tumor activity.21 All knockout Id4 mice 




differentiation and normal brain development.78  However, according to all previous data, 
it is highly suggestive that ID4 act as tumor suppressor in prostate cancer. 
2.6.2 ID4 in Development 
ID proteins are expressed by all cell lineages at some point during embryonic 
development. Unlike other ID proteins, ID4 is highly expressed during premature 
differentiation of early cortical stem cells.79 Accumulating evidence also suggest that ID4 
expression is relatively high in undifferentiated, proliferating populations and is 
subsequently down-regulated as these cells begin to exit from cell cycle and get 
terminally differentiated.9 In adult human tissues, ID4 expression is observed in the brain, 
thyroid, testis, and pancreas.80 Moreover, ID4 is highly expressed in osteoblasts,80 
adipocytes,81 prostate epithelial cells,82 neurons,71 testicular sertoli cells, and also in glial 
cells during differentiation,82 further supporting its role as a pro-differentiation factor. 
ID4 plays an essential role in the development of different organs including neural 
compartments, normal mammary,83 and prostate gland.84 In oligodendrocyte progenitor 
cells (OPCs), overexpression of ID4 inhibits differentiation along with a subsequent 
decrease in the endogenous expression of all myelin genes.85 Moreover, OPC’s lacking 
ID4 display early differentiation and increased apoptosis, further implicating the critical 
role of ID4 in the development of oligodendrocytes.86 In addition, ICC studies have 
shown that ID4 is localized to the nucleus in OPC’s and spermatids, but remains 
cytoplasmic in spermatocytes.87 The integration of various cellular events including 
response to specific ligands and cell specific protein-protein interactions could also 




localization. Collectively, these studies suggest that ID4 can act as pro- or anti-
differentiation factor in a cell specific manner  
2.6.3 ID Proteins and Stem Cells. 
Previous studies have been shown that ID1, ID2, ID3 are primarily involved in 
maintaining tissue stemness in embryo development via inducing NANOG activity 
though dimerization with bHLH protein 71. Jung S, and co-workers show that Id1, Id2, 
and Id3 increase self-renewing and proliferation potential of cortical neural stem cells 
(NSCs) while inhibiting neuronal differentiation. In electrophoretic mobility gel shift and 
luciferase assays, Id proteins interfered with binding of NeuroD/E47 complexes to the E-
box sequences and inhibited E-box-mediated gene expression. Overexpression of Id 
proteins in NSCs increased both the number and the size of neurospheres in colony-
forming assays.88 
2.6.4 ID4 and Cancer Stem Cells 
Studies on knockout mice revealed that ID4 is required for normal brain size and 
regulate neural stem cells proliferation and differentiation. Several different studies 
demonstrated that glioblastoma; increase ID4 expression level can maintain its cancer 
stemness, but no one has demonstrated that loss of ID4, maintain prostate cancer 
setmness. Studies on cancer stem cells in Stanford University suggested that there is link 
between ID4, FOXO1 and stem cell maintaining transcription factors NANOG, SOX2, 
and OCT4.54 Our previous studies on ID4 knockout mice, demonstrated that loss of ID4 
attenuate normal prostate development and promote hyperplasia /dysplasia with subtle 




expression. Also, our preliminary data show that loss of ID4 increases the expression of 
Sca-1, which is a mouse stem cell marker.  
2.6.5 ID4 Protein Interaction 
HES1, TCF3/4 and TWIST1 are the main proteins that interact with ID4. Apart 
from that our lab has shown that ID4 may act as a co-chaperone and interact with Hsp90, 
FKBP52 which are also important in the regulation of AR. Our preliminary data suggest 
that ID4 has interaction with FOXO1 to regulate the action of AR and FOXO1 action 
itself.   
2.6.6 FOXO1  
The forkhead transcription factor family is characterized by a winged-helix DNA 
binding motif and the forkhead domain.89 The mammalian forkhead transcription factors 
of the O class (FOXOs) have four members: FOXO1, FOXO3, FOXO4, and FOXO6. 
FOXO1 and FOXO3 are expressed in nearly all tissues. Studies have demonstrated that 
FOXOs play critical roles in a variety of cellular processes. FOXOs transcriptionally 
activate or inhibit downstream target genes, by playing an important role in proliferation, 
apoptosis, autophagy, metabolism, inflammation, and differentiation. Germline deletion 
of FOXO1 is lethal and it causes embryonic cell death due to incomplete vascular 
development.89 FOXO transcriptional activity is regulated by a complex array of 
posttranslational modifications, either activating or inactivating, results in alter nuclear 
import and export steps, modify the DNA binding affinity, and alter the pattern of 
transcriptional activity for a specific target.90 FOXOs share significant sequence 




localization, nuclear export, and transactivation domains. FOXO proteins have both a 
nuclear localization sequence and a nuclear export sequence within the C-terminal DNA 
binding domain. AKT/SGK protein kinases phosphorylate FOXO1 and FOXO3 at well-
defined sites, which increase the association with chaperone proteins results in the 
translocation of FOXO proteins from the nucleus to cytoplasm leading to their 
transcriptional inactivation.79 Phosphorylation of FOXO by AKT also disrupts FOXO 
interactions with DNA. 
Acetylation, controlled by the histone acetyltransferase and histone deacetylases, 
has been shown to both promote and decrease FOXO transcriptional activity and to 
mediate different biological functions of FOXOs.91 In FOXO1, CREB binding protein 
induced acetylation at two basic residues, Lys242 and Lys245 located in the C-terminal 
region of the DNA binding domain, has been shown to reduce its DNA binding affinity 
and transcriptional activity. 
     Arginine is a positively charged amino acid known to mediate hydrogen bonding and 
amino-aromatic interactions. Studies showed, PRMT1 methylates FOXO1 primarily at 
Arg248 and Arg250 that are conserved within the consensus Akt phosphorylation motif. 
This arginine methylation directly abrogates Akt-induced phosphorylation of FOXO1 at 
Ser253, which in turn results in increased nuclear localization and inhibition of 
subsequent degradation. This methylated FOXO1 mediate OCT4 and SOX2 gene 
expression through occupation and activation of their respective promoters to maintain 





2.6.7 PRMT  
Arginine methylation is a common post-translational modification (PTM), with 
around 2% of arginine residues methylated in experimented with mouse liver.92 This 
arginine methylation in mammalian cells is carried out by a family of nine protein 
arginine methyltransferases (PRMTs). PRMTs are constitutively active and display basal 
activity without requiring processing or PTMs. However, mechanisms for fine-tuning 
PRMT activity may be seen through PTMs, association with regulatory proteins, 
subcellular compartmentalization and through factors that affect enzyme-substrate 
interactions.93 
Each addition of a methyl group to an arginine residue removes a potential 
hydrogen bond donor and changes its shape. For example, arginine dimethylation 
imparts bulkiness and hydrophobicity to a protein and can affect protein–protein 
interactions, both positively and negatively.94 Importantly, methylation does not 
neutralize the cationic charge of an arginine residue. There are 9 isotypes of PRMTs 
presence in cellular fiction and from them, PRMT1 and PRMT5 are the major 
asymmetric and symmetric arginine methyltransferases, respectively, and the complete 
loss of either of these enzymes is not compatible with the mouse or cell viability.95 
Nevertheless, PRMT1 knockout studies demonstrate it is required for genome integrity 
and cell proliferation. 
Alteration of PRMT1 expression, mostly upregulation, has been observed in 




and its activity accounts for >90% of the methylarginine residues in mammalian cells.87 
With regard to histone methylation, PRMT1 specifically deposits an asymmetric 
dimethylation arginine mark on histone H4 at arginine 3 (H4R3me2a). This histone 
methylation can either repress or activate transcription. In breast cancer, TDRD3 gene 
activate and progress to metastasis.94 
Large numbers of non-histone substrates for PRMT1 have been identified. 
PRMT1more directly regulate the AKT signaling pathway. They have shown that 
PRMT1 mediated methylation of RxRxxS/T protein sequences blocks AKT 
phosphorylation at serine or threonine residues. A good example of this is FOXO1, 
which is methylated in vitro and in cells by PRMT1 at residues R248 and R250. PRMT1 
mediated arginine methylation of R248 and R250 blocked FOXO1 S253 
phosphorylation. The treatment of cells with hydrogen peroxide led to an increase in the 
PRMT1 dependent methylation of FOXO1, which in turn blocked the AKT 
phosphorylation of S253 and nuclear export. As a result, the transcription of a number of 
FOXO1 target genes was increased. Likewise, PTMT1 is very important in the  
regulation of many transcription factors either by histone methylation or non-histone 
protein methylation.94  
2.7 ID4 in prostate Cancer: Tumor Promoter vs Tumor Suppressor 
In comparison to other ID proteins, the function of ID4 is less understood and 
often conflicting. The specific nature of ID4 protein expression in cancer has not been 




ID4 appears to act primarily as a tumor suppressor in most cancers as opposed to ID1, 
ID2, and ID3 which acts as tumor promoters or supporting oncogenes. In a small subset 
of cancers, ID4 also acts as a tumor promoter.97 For instance, high ID4 expression in a 
B-cell acute lymphoblastic leukemia81 and B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL)98 due to (6;14)(p22;q32) chromosomal translocation, breast,99 
bladder,100 and in rat mammary gland carcinomas73 suggests that it may have pro-tumor 
activity as well. Overall, recent studies have concluded that ID4 is highly expressed in 
the normal prostate and decreased in prostate cancer primarily due to promoter hyper-
methylation at the epigenetic level.31 
1. ID4 Expression in Normal Prostate 
     Oncomine database suggested that ID4 is highly expressed in the normal prostate and 
its expression decreases in prostate cancer (Figure 3). The ID4 expression in normal 
human prostate is also consistent with its expression in the mouse prostate (Figure 4). 
Results from tissue microarray (TMA) also showed that ID4 is highly expressed in 
normal prostate whereas its expression decreases with increase in cancer progression 






Figure 3. Oncomine Database Shows that ID4 Expression is Regulated in Prostate Cancer.      
                                                                                   
 





Figure 5. Prostate cancer tissue microarrays were used to investigate ID4 expression. ID4 was 
highly expressed in normal prostate (A) 200X and (B) 400X as seen by intense brown staining in 
the nuclei. Overall, ID4 expression decreased with increasing grade of prostate cancer (C) grade I 
(200X), (D) grade I (400X), (E) Grade II (200X), (F) grade II (400X), (G) Grade III (200X), and 
(H) Grade III (400X). The sections are also representative of scores used to quantify staining 
intensity: A and B – score 3; C and D – score 2; E – score 0. ID4 is mostly nuclear as seen by 
intense nuclear staining (brown, indicated by red arrow in D). At higher stages a clear large 
nucleus with no apparent brown staining is observed (yellow arrow in D and F). The sections 
were counterstained with hematoxylin that is reflected in the blue nuclei observed primarily in 
prostate cancer sections with undetectable Id4 expression. The 400X images in panels B, D, F, 
and H are corresponding images of boxed regions shown in panels A, C, E, and G (2009). The 
inset in panel G is the 4009 image of the region showing high Id4 expression in normal prostate 









2.7.1 ID4 is Epigenetically Silenced in Cancer: 
Studies performed in cancers such as prostate, breast, colorectal and lymphoma 
have shown that ID4 is epigenetically silenced due to promoter hypermethylation. The 
specific nature of ID4 protein expression in cancer has not been clarified, however, 
studies support that ID4 has both pro-tumor and anti-tumor activity. Epigenetic silencing 
of ID4 in leukemia,101 breast,21 colorectal, mouse and human chronic lymphocytic 
leukemia (CLL), and gastric cancer tend to support its antitumor activity.101  
ID4 Methylation in Prostate cancer cell lines with respect to its expression 
Previous studies demonstrated that ID4 expression is high in LNCaP cells, low in PC3 
cells and absent in DU145 cells. Methylation specific PCR indicate ID4 promoter 
methylation in DU145, PC3 cells No ID4 promoter methylation was observed  in LNCaP 
cells, whereas the progressively castration resistant derivatives of LNCaP cells, the C81 
and C33 showed increasing ID4 promoter methylation (Figure 6)  ID4 was also 
methylated in majority of prostate cancer samples as opposed to benign prostate 
hyperplasia and adjacent normal epithelial cells as determined by methylation specific 








Figure 6. ID4 Promoter methylation status was seen in DU145, with no ID4 expression. In c-33, 






Figure 7. Laser capture micro-dissection (LCMD) was used to examine ID4 methylation in 41 
prostate cancer samples, 19 benign and adjacent normal regions and 4 benign stroma adjacent to 








2.7.2 ID4 and Epithelial Differentiation 
According to microarray data set, in mouse stem cell differentiation pathway, 
prostate stem cells and transient amplifying cells (TAC) do not express ID4 (Stemness of 
these cells are confirmed by the expression of mouse stem cell marker “sca1”).102 ID4 
expression gradually increases as TAC differentiates into prostate epithelial cells (Figure 
8).   
Sca-1 negative differentiated epithelial cells do not express CK14 and CK5, which are 
keratins that express in urogenital sinus stem cells and developing prostate and are considered as 
basl cell markers. This data suggest Id4 has a major effect on the differentiation of prostate 
stem cells to epithelial cells.  The data also suggests that the expression of NKX3.1, a 
prostate epithelial cell marker also increases concomitantly with Id4 expression. 
Interestingly, AR expression appears in Sca los TAC cells suggesting that AR expression 





Figure 8. Microarray Data of Mouse Epithelial Differentiation. 
2.7.3 ID4 and Prostate Development  
Previous study on 6 weeks of ID4 knockout mice prostate showed that size of the 




clear that loss of ID4 attenuates prostate development by restricting total gland 
development and branching morphogenesis. 
 
Figure 9. Effect of loss of Id4 on mouse prostate development. A and B – Immuno-histochemical analysis 
of Id4 expression in the wild type mouse prostate. Panel B is the enlarged version of the box represented in 
Panel A. Id4 expression is primarily localized to epithelial cell nuclei. Red, green and yellow arrow heads 
represent cells expressing high, low or no Id4 respectively. C: Lack of Id4 expression in Id4-/- prostates. 
The scale bars are 100um. D: The relative size of the genital tract (excluding testis and epididymis) of the 
wild type (Id4+/+) and mutant (Id4-/-) mice. The representative image of three different tracts 
demonstrating clear size differences is shown. The bottom panel represents the size of the seminal vesicle 
from the Id4+/+, Id4+/- and Id4-/- mice. E: Average number of tubules and tubule diameter per cross 
section in the wild type and Id4 -/- prostates. The number of tubules were counted in each section (n = 100 
serial cross sections for Id4+/+, n = 76 for Id4+/- and n = 54 for Id4-/, proximal to distal) at 50× and their 
mean ± SEM is indicated as open bars. The black bars represent average tubule diameters (±SEM) of the 






2.8 Tumor Markers  
There are different proteins used to identify tumors in tissues to detect tumor 
grade, severity and treatment progression. These proteins are called tumor markers. 
AMACR and NKX3.1 are the most common proteins which are used in 
immunohistochemistry in human prostate tissue. Apart from them probasin and Sca-1 
are used to identify the stemness and AR activity in mice prostate tissues. 
2.8.1 AMACR 
Alpha-methylacyl-CoA racemase in humans is encoded by the AMACR gene. In 
mammalian cells, the enzyme is responsible for converting (2R)-methylacyl-CoA esters 
to their (2S)-methylacyl-CoA epimers and known substrates, including coenzyme A 
esters of pristanic acid (mostly derived from phytanic acid, a 3-methyl branched-chain 
fatty acid that is abundant in the diet) and bile acids derived from cholesterol. This 
transformation is required in order to degrade (2R)-methylacyl-CoA esters by β-
oxidation, which process requires the (2S)-epimer.103 The enzyme is known to be 
localized in peroxisomes and mitochondria, both of which are known to β-oxidize 2-
methylacyl-CoA esters. Increased levels of AMACR protein concentration and activity 
are associated with prostate cancer and the enzyme is used widely as a biomarker in 
biopsy tissues.103 Increased levels of AMACR are also associated with some breast, 
colon, and other cancers. According to literature, positive AMACR immunostaining 
along with negative basal cell markers (P63) is used in the differentiation of atrophic 





NKX3-1 is an androgen-regulated, prostate-specific homeobox gene whose 
expression is predominantly localized to the prostate epithelium. It acts as a transcription 
factor that has a critical function in prostate development and tumor suppression. In 
humans, the NKX3-1 gene is located on chromosome 8p21.2 with 4 exons. Mouse 
studies demonstrated that at 15.5 dpc (days postcoitum), NKX3.1 mRNA is expressed in 
urogenital sinus whereas NKX3.1 protein expression starts at 17.5 dpc. This expression 
precedes formation of prostatic bud, indicating that NKX3.1 is responsible for prostate 
epithelial branching and morphogenesis. NKX3.1 -/- mouse showed that it has normal 
prostate with 40% less branching morphogenesis compared to wild type mouse. The12 
months old NKX3.1-/- mouse developed histological features that resemble human PIN, 
which is thought to be the primary precursor of prostate cancer. 
NKX3-1 has been established as a marker for identifying metastatic tumors. 
Furthermore, anti-NKX3-1 antibodies are a more sensitive and specific method for 
diagnosing metastatic prostatic adenocarcinomas in distant sites.104 
2.8.3 Probasin 
The prostate gland will produce a number of tissue-restricted gene products. 
Characterization of the regulation, expression, and function of genes encoding prostate-
specific proteins is critical to our understanding of prostate biology. Probasin is a 
prostate-specific gene originally isolated from the rat and has been exploited as a marker 





Sca-1 stands for "Stem cells antigen-1". It consists of 18-kDa mouse glycosyl 
phosphatidylinositol-anchored cell surface protein (GPI-AP) of the LY6 gene family. It 







MATERIALS AND METHODS 
 
3.1 Prostate Cancer Cell Lines 
Human prostate cancer cell lines LNCaP, DU145 and PC3 were obtained from 
American Type Culture Collection (ATCC, Rockville, MD) and cultured as per ATCC 
recommendations as described previously.5 PC3 and DU145 cells were cultured in Ham’s 
F12 (Gibco, Carlsbad, CA) medium containing 10% bovine calf serum (Hyclone, Logan, 
UT) with appropriate antibiotics (pen/strep, fungizone, and gentamycin). LNCaP cells 
were cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS) and appropriate 
antibiotics. Cells were cultured at 37°C in a fully humidified atmosphere containing 5% 
CO2. 
3.2 ID4 Silencing in Prostate Cancer Cell Lines 
The prostate cancer cell line LNCaP was used to stably silence ID4 using gene-
specific short hairpin RNA retroviral vectors (Open Biosystems #RHS1764 -97196818, - 
97186620 and 9193923 in pSM2c, termed as ID4shRNA A, B, and C respectively). 
LNCaP cells transfected with non-silencing shRNA (RHS1707) (L+ns) was used as a 
control cell line. Transfections and selection of transfectants (puromycin) were performed 




Successful silencing of ID4 gene was confirmed via qRT-PCR and western blot analysis. 
  
3.3 RNA Extraction 
Total RNA from L+ns, L(-)ID4, DU145 and DU145(+)ID4 cells were isolated by 
an E.Z.N.A. DNA/RNA kit (Omega Bio-tek). The final RNA pellet was re-suspended in 
diethyl pyrocarbonate (DEPC)-treated H2O, quantified as per the manufacturer’s 
instructions and then stored at -80°C until further analysis. 
 
3.4 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
  RNA (2 µg) isolated from cells was reverse transcribed to a final volume of 25µl 
as per the standard protocol,15, 98 (RT Master Mix: 1.25 mM each of dNTP’s, 250 ng 
oligo DT (Promega, Madison, WI), 10 mM dithiothreitol, and 200U MMLV reverse 
transcriptase (In-vitro) in the MMLV first-strand synthesis buffer (Invitrogen). RNA 
previously suspended in DEPC water was first denatured for 10 minutes at 65ºC, and then 
cooled on ice for 2 minutes before addition of reverse transcriptase master mix. The 
reverse transcriptase reaction was carried out in a thermocycler at 42ºC for 1 hour and 
95ºC for 5 minutes. The reverse transcribed RNA was stored at -20ºC until further 
analysis. 
 
3.5 Quantitative Real Time PCR (qRT-PCR) 
The reverse transcribed RNA from cell lines was used to perform RT-PCR and/or 




(respective gene value - Ct value subtracted from GAPDH Ct) and ΔΔCt values (fold 
change as compared to the gene expression levels in L+ns samples) were used as a 
quantitative measure of gene expression. 
Table 1. Primer Sequences for RT-PCR, and Real-time qRT-PCR 
        PCR Primers              Forward ( 5’)     Reverse ( 5’) 
      GAPDH    GAAGGTGAAGGTCGGAGTC   GAAGATGGTGATGGGATTTC 
      CD44    AACCACAAGGATGACTGATG   TTCTGGGTAGCTGTTTCTTC 
      CD133    CTCCCTGTTGGTGATTTGTA   ATTCAAGAGAGTTCGCAAGT 
      FOXO1    TGTCCTACGCCGACCT   TGCTGTGTAGGGACAGATTA 
      NANOG    AGGGATGCCTGGTGAAC   AGAGATTCCTCTCCACAGTT 
     OCT4    AGGAAGCTGACAACAATGAA   CACTGCAGGAACAAATTCTC 
     SOX2    CGGATTATAAATACCGGCCC   CATGTGCGCGTAACTGT 
 
3.6 Protein Extraction 
Total cellular proteins were prepared from the cultured prostate cancer cell lines 
using M-PER (Thermo Scientific). Protein samples were quantitated using the BCA 
Protein Assay Kit according to manufacturer’s protocol (Thermo Scientific). A standard 
curve was determined using BSA and the absorbance values of the unknown protein 
samples were determined at a wavelength of 562 nm. Respective protein samples 
(20μg/μl) were then mixed 1:1 with 2X laemmli sample buffer for subsequent western 







3.6.1 Nuclear Cytoplasmic Extraction 
Approximately 4 x 107 cells were prepared and washed gently with PBS buffer. 
Cells were obtained by centrifugation using a micro-centrifuge at 10,000 rpm and 
resuspended the pellet in 5 times pellet volumes of CE buffer (approximately 100 μl). 
Cells were incubated on ice for 3 min and then centrifuged by a micro-centrifuge at 
10,000 to 15,000 rpm for 4 min. To obtain cytoplasmic proteins, the supernatant was 
removed from the pellet to a clean tube, and the pellet was washed with 100 μl of CE 
buffer without detergent and centrifuged at 10,000 to 15,000 rpm for 4 min. Salt 
concentration was adjusted to 400 mM using 5 M NaCl (~35 μl). To obtain the nuclear 
proteins, 1 pellet volume of NE buffer was added to nuclear pellets (approximately 50 μl) 
and an additional pellet volume of NE buffer was added respectively. The protein extracts 
were incubated on ice for 10 min and vortexed periodically to re-suspend the pellet. 
Lastly, the CE and NE proteins were centrifuged at maximum speed for 10 min to pellet 
any nuclear proteins and were transferred the contents of the CE tube and NE tube 
separately to clean tubes. Glycerol was added to the CE tube to 20%, and Stored at -
70°C. 
 
3.7 Western Blot Analysis 
  20 μg of total proteins were size fractionated on 4-20% SDS-polyacrylamide gel. 
The SDS-gel was subsequently blotted onto a nitrocellulose membrane (Whatman) and 




washing with 1x PBS, 0.5% Tween 20, the membranes were incubated with horseradish 
peroxidase (HRP) coupled secondary antibody against rabbit/mouse IgG and visualized 
using the Super Signal West Dura Extended Duration Substrate (Thermo Scientific) on 
Fuji Film LAS-3000 Imager. 






3.8 Colony Formation Assay 
  The hierarchy of colony forming cells described by Barrandon and Green is 
recapitulated by certain types of normal cell in culture 47,104and consequently colony 
morphology is used routinely as a surrogate assay to identify and characterize stem cells. 
Holoclones express survival and self-renewal genes associated with stem cell capacity. 
Holoclones, meroclones, and paraclones were described in clones derived from human 
cancer cell lines of various types, including pancreatic47, head and neck58, breast105and 
prostate.106 Cancer cell holoclones can be passaged indefinitely107 and xenografted 
serially.108 The formation of holoclones has been adopted as a surrogate stem cell assay, 
particularly in the study of prostate cancer.109 An increased number of holoclones is 
regarded as enrichment for cancer stem cells (CSC) and has been used to study CSC 
marker expression. In prostate cancer, an increased number of holoclones is associated 
with the expression of the putative stem cell markers CD44, integrin a2b1, CD133, 
PSAlo expression110and aldehyde dehydrogenase 1 (ALDH) activity.111 Holoclone 
formation has also been used to validate sphere formation from cell lines as a stem cell 
assay112 and to demonstrate the presence of cancer stem cells in samples from primary 
human prostate cancers. 
Two hundred cells from prostate cancer cells were plated on 60mm petri dish and 
let cells to grow for two weeks and every day evaluates the morphology of cells. After 




identified and counted. Using cloning cylinders, different colonies were selected and 
reculture them based on holoclone, meroclone, and paraclone.   
3.9 FACS Analysis 
Flow cytometry permits the visualization and sorting of cells according to the 
presence of antigens which are detected through fluorescently labeled antibodies, which 
when bound and excited with a laser can be detected. This allows a quantitative technique 
to compare protein expression between samples. A FACSCanto II flow cytometer (BD 
Biosciences) was used for flow cytometry analysis and a FACSAria (BD Biosciences) 
was used for sorting. With the exception of apoptosis assays, viable cells were gated on 
using FSC and SSC. Unstained cells, single color controls, and fluorescence minus one 
(FMO) controls were used for compensation analysis and to set appropriate gates for 
analysis. Data was acquired using BD FACSDiva (BD Biosciences) and analysis was 
performed using FlowJo (Tree Star Inc., Ashland,USA) software. 
Antibody Staining 
All antibodies were titrated for optimal concentration before use. Antibodies used 
in this study are described in Table 2. Controls consisted of an appropriate isotype 
matched antibody at the same concentration. Isotype controls were used for all human 
antibodies used.  
Cell Surface Antibody Staining 
An appropriate number of cells were centrifuged at 300 x g for 5 min and washed 
several times. Cells were resuspended in PBS/2% FCS with antibodies at an appropriate 




protocol. After staining, cells were washed, resuspended in 200µl PBS/2% FCS and 
analyzed. Cells required for sorting were filtered using a 0.2µM filter prior to use. 
 
3.10 Animal Studies 
3.10.1 Preparation of Tumor Stem Cells 
LNCaP cells were grown in complete medium (10% v/v FBS in RPMI-1640 
medium). When cells were 70-80% confluent, 3-4 hours before harvesting, the medium 
was replaced with fresh medium to remove dead and detached cells. Then the medium 
was removed, and cells were washed with PBS. After adding an appropriate amount of 
trypsin-EDTA, cells were dispersed by adding complete medium (5:1), and then 
centrifuged immediately at 1500 rpm for 5 minutes. After re-suspending the cell pellet 
with complete medium (1:1), cells were counted using a Cellometer Vision Trio 5 system 
(Nexcelon Bioscience). Cells were sorted with FACS based on CD133 surface marker. 
 
3.10.2 Tumor Inoculation 
The work area was prepared by disinfecting all hood surfaces with 70% ethanol. 
The inoculation area of each mouse was cleaned and sterilized with an alcohol pad. A 
freshly prepared cell suspension was agitated to prevent the cells from settling and then 
mixed with matrigel. One hundred microliters of the mixture (containing 10000 LNCaP 
CD133 positive cells) were injected subcutaneously into the lower flank of each of the 3 
(4-weeks old) castrated C.B-17 SCID mice and control 10000 LNCaP CD133 negative 




were maintained at the Mercer University Vivarium. All studies were approved by the 
Clark Atlanta and Mercer University Committee for the use and care of animals 
(IACUC). Tumor diameters were measured with digital calipers.  At the end of the 
experiments, the mice were laid to rest by asphyxiation, the tumors were surgically 
removed, weighed and the volume was measured. Harvested tumors were fixed in 10% 
buffered formalin. The fixed tumors were paraffin-embedded, sectioned (5 μm), and 
either stained with hematoxylin and eosin (H&E) or used for IHC. Images were captured 
using a Zeiss microscope with an Axiom Cam version 4.5 imaging system. 
 
3.11 Immunohistochemistry 
IHC protein localization studies in paraffin-embedded 5-μm tissue sections were 
performed using protein specific antibodies. Briefly, the slides were deparaffinized in 
xylene and re-hydrated through standard protocols. Following antigen retrieval (autoclave 
in 0.01 M sodium citrate buffer pH 6.0 at 121°C /20 psi for 30 minutes), the peroxidase 
activity was blocked in 3% H2O2 and nonspecific binding sites blocked in 10% goat 
serum. The blocked sections were incubated overnight at 4°C with protein specific 
primary antibodies followed by incubation with secondary antibody (Table 3) for 1 hour. 
The slides were stained with DAB for 2 minutes, counterstained with hematoxylin, 
mounted with immuno-mount (Thermo Scientific), examined, and photo-micrographs 
were taken using the Zeiss microscope with an AxioVision version 4.5 imaging system. 
All the antibodies were mono-reactive, that is a single reactive band was observed in 








Cells were grown on glass chamber slides up to 75% confluency in a 6-well plate. 
Twenty-four hours after plating, the complete medium with 10% FBS was replaced with 
10% charcoal-stripped media (csFBS). The slides were then washed with PBS (3x) and 
fixed in ice-cold methanol for 10 minutes at room temperature and stored at 4°C until 
further use. Before use, the slides were equilibrated at room temperature, washed with 
PBS (5 minutes x 3), blocked with 1% BSA in PBST for 30 minutes at room temperature 
and incubated overnight (4°C) with protein specific antibodies (1% BSA in PBST, Table 
3). The slides were then washed in PBS and incubated with the secondary antibody with 
fluorochrome conjugated to DyLight (Table 3) in 1% BSA for 1 hour at room 
temperature in dark. The slides were subsequently washed again and stained in DAPI (1 
µg/ml) for 1 minute and mounted with glycerol. Images were acquired by Zeiss 
fluorescence microscope through Axiovision software. 
 
3.13 Co-Immunoprecipitation (Co-IP) Analysis 
L+ns and L(-)ID4 cells were serum-starved for 24 hours, prior to treatment with 
R1881 (10 nM) for additional 24 hours Next, co-immunoprecipitation (Co-IP) analysis 
was performed using protein A coupled to magnetic beads (Protein A Mag beads, 




FOXO1) was first immobilized to Protein A Mag Beads by incubating overnight at 4°C. 
To minimize the co-elution of IgG following immunoprecipitation, the immobilized IgG 
on protein A Mag beads was cross-linked in the presence of 20 mM dimethyl 
pimelimidate dihydrochloride (DMP) in 0.2 M triethanolamine, pH 8.2, washed twice in 
Tris buffer (50 mM Tris pH 7.5) and 1x PBS followed by final re-suspension and storage 
in 1x PBS. The cross-linked protein specific IgG-protein A-Mag beads were incubated 
overnight (4°C) with freshly extracted total cellular proteins (500 µg/ml). The complex 
was then eluted with 0.1 M Glycine (pH 2-3) after appropriate washing with 1x PBS and 
neutralized by adding 10 μl of neutralization buffer (1 M Tris, pH 8.5) per 100 µl of 
elution buffer. Eluted proteins were subjected to SDS-PAGE, transferred to nitrocellulose 
membrane, and then immunoblotted with protein specific antibodies.  
 
3.14 Statistical Analysis 
The National Institutes of Health (NIH)ImageJ,110 was used for counting cells 
stained positive for respective antigens in the IHC studies.111 Quantitative real-time 
(qRT-PCR) data were analyzed using the ΔΔCt method.112 Data is expressed as mean ± 
SD from three different experiments. Within groups, statistical analyses were performed 





CHAPTER IV  
RESULTS 
 
4. Id4 Knockout Mice Analysis of Prostate 
Previous studies on Id4 knockout mice (Sharma et al) prostate have shown 
attenuation of prostate development.31 Levels of androgen receptor were similar between 
wild type and Id4-/- prostate. Decreased NKX3.1 expression was in part due to 
decreased androgen receptor binding on NKX3.1 promoter in Id4-/- mice. The increase 
in the expression of Myc, Sox9, Id1, Ki67 was noted up to the age of 6 weeks. In this 
study, H&E and IHC were performed up to 6 months’ age prostate tissue. 
 
4.1 H&E Staining  
H&E staining of Id4 -/- mice prostate has less differentiation and fewer tubules 
formation compared to wild type prostate. At the age of 3 months and 6 months, Id4 -/- 
prostate shows initial tufting, micropapillary, and cribriform appearance suggesting PIN 
like lesions, without features of prostate cancer as seen in Pten +/-,105 Nkx3.1 -/- mice 
models,105 where they develop prostate cancer at the age of 3 months (Figure 10).  







Figure 10. H & E Staining mice prostate at 25 days, 3months and 6 months. 
4.2.1 AMACR Expression 
AMACR tissue immunohistochemistry is widely used as a prostate cancer 
biomarker.106 The expression of AMACR has also been observed in high-grade prostatic 
intraepithelial neoplasia (PIN), a precursor lesion of prostate cancer. In 3 months and 6 




levels were observed   in 25 days as compared to wild type mice prostate that do not 
express AMACR (Figure 11). This suggests the presence of lesions, but full blown 
cancer is not visible (except in some regions of hyperplasia).  
 
Figure 11. Expression of AMACR.  
4.2.2 NKX3.1, Probasin and AR Expression  
AR expression is equal in both Id4-/- and wild type at the age 25days, 3 months 
and 6 months indicating AR has its transcriptional  regulatory network intact throughout 
the life.  AR behaves as pro-differentiation and meta-stably in normal prostate. Also, AR 
behaves as pro-survival, hyper-sensitive and hyper stable state in prostate cancer. 




AR driven tumor suppressor gene NKX3.1 expression is essentially undetectable in Id4-
/- mice at 6 months.  NKX3.1 positive cells (nuclei and cytoplasmic) are occasionally 
observed at 3 months’ prostate.  NKX3.1 expression is rarely observed at 25d old 
prostate with the exception of some staining in inter-tubular tracts (most likely 
background staining).  These results suggested that ID4 regulates NKX3.1 and that its 
expression precedes NKX3.1 or ID4 loss blocks cellular differentiation pathway 
including expression of effectors that may be required for NKX3.1 expression (Figure 
12). 
There is no change in probasin, an androgen receptor driven gene specific for 
mice prostate (similar to PSA in human), expression in Id4-/- and wild type mouse 
prostate. These result suggested that ID4 has minimal or no effect on regulation of 
probasin expression in mouse prostate epithelial cells. 
 





  Sca-1 is a "Stem cells antigen-1". Sca-1 is highly expressed in mouse prostate 
stem cells and is non-detectable in differentiated prostate epithelial cells. Sustained 
expression of Sca-1 in mouse prostate suggests that loss of Id4 block prostate epithelial 
cell differentiation. Sca-1 expression is essentially similar in wild type and ID4-/- mouse 
prostate at 25 days. Mouse prostate development is complete around 20 days after birth. 
Sca-1 expression in wild type and ID4-/- mouse prostate is compatible with mouse 
prostate development. The 3 months and 6 months old wild type prostate do not express 
sca-1, while Id4-/- mice express sca-1, indicating ID4 has an effect on epithelial 
differentiation (Figure 13). This result is compatible with prostate development heat map 
data (Figure 8). 
 




4.2.4   Pten, Akt and P-Akt 
Pten expression is not observed in 25 days, 3 months and 6 months Id4-/- mouse 
prostate. Loss of Pten faction results in accumulation of PIP3 and phosphorylation of its 
downstream target AKT that leads to cell proliferation. IHC data shows increased p-AKT 
expression in Id4-/- mouse prostate compared to wild type mouse prostate in 25 days, 3 
months and 6 months. Previous study shows that Pten -/- mouse developed prostate 
adenocarcinoma at the age of 3 months whereas, the data from our study shows that it 
can develop only pin like lesions at the age 6 months.  This indicates that Id4-/- has the 
potential to initiate prostate cancer without developing in to adenocarcinoma, that may 






Figure 14. Expression of  Akt, P-Akt and Pten in wild type and Id4-/- prostate gland in 25 days, 




Knockout mice studies suggest that loss of Id4 has the effect on prostate luminal 
epithelial differentiation by maintaining stemness and initiate lesions and has the 
potential to develop prostate carcinoma. Based on this strong evidence, the effect of ID4 
on prostate cancer cells will be investigated to test my hypothesis and specifics aims.   
4.3 Colony Formation 
There is overwhelming evidence supporting the concept that only a specific group 
of cells, among the cellular heterogeneity of a tumor, possesses self-renewal and 
multilineage differentiation potential and is, therefore, responsible for tumor 
development. These cells, so called "tumor initiating cells" (TICs) or "cancer stem cells" 
(CSCs), have been documented in most circulating and solid tumors as well as in 
numerous established cancer cell lines 
Charlotte and coworkers studied the colony formation of prostate cancer cells 
lines, and based on the morphological appearance they were named as holoclone, 
meroclone, and paraclones.47 LNCaP, LNCaP (-) ID4, DU145 and DU145 (+) ID4 cells 
form all three kinds of colony in-vitro. Holoclone has denser cell aggregation, less 
aggregation on meroclone and very loose or discrete in paraclones (Figure 15 a). 
Holoclone diameter is about 1 mm and it has about 1500 cells whereas microcline has 
about 750 cells and paraclone has about 250 cells in one colony. Prostatosphere 
formation on LNCaP and LNCaP (-) ID4 cells on matrigel demonstrate similar 
appearance of holoclone formed in normal media in the petri dish (Figure 15 b). Also 










Figure 15.  a) Microscopic appearance of Holoclone , Meroclone and Paraclones in 
LNCaP, LNCaP(-) ID4, DU145 and DU145(+) ID4 cells. b) Microscopic appearance of  
Prostatosphere in matrigel  on LNCaP and LNCaP(-) iD4 cells. c) Prostatosphere count frequency 







4.4 Anchorage Dependent Growth 
Using LNCaP, LNCaP (-) ID4, DU145 and DU145 (+I) D4 cellular models, 200 
individual cells were plated in 60 mm petri dish to facilitate the colony formation. After 2 
weeks of inoculation, colonies were counted based on their morphology: holoclone, 
meraclone, and paraclone. From each colony, re-culturing was performed for several 
generations and the subsequent colony were counts were recorded. In the first round of 
cloning, 80 holoclones, 32 meroclones and 27 paraclones were developed from 200 
LNCaP cells (Figure 16 a). It developed 24 holoclones, 47 meroclones and 38 paraclones 
from holoclones. 21 holoclones, 67 meroclones and 31 paraclones were developed from 
meroclones whereas 3 holoclones, 34 meroclones and 47 paraclones were developed 
from paraclones in 2nd cloning. During 3rd cloning, it developed 18 holoclones, 63 
meroclones and 36 paraclones . 14 holoclones, 61 meroclones and 62 paraclones were 
developed from meroclones whereas 2 holoclones, 34 meroclones and 63 paraclones 
were developed from paraclones. Similarly, LNCap (-) ID4 cells results demonstrate a 
significant increase in the ability of LNCaP (-) ID4 cells to form holoclones, further 
implicating an increased stemness in the LNCaP (-) ID4 generated holoclones. Further in 
DU145 cells shows a similar pattern of holoclone formation in relation to ID4 expression 





Figure 16. d) Colony count frequencies of LNCaP and LNCaP (-) ID4 cells in colony 
formation assay. e) Colony count frequencies of DU145 and DU145 (+) ID4 cells in colony 
formation assay.  
 
4.5 Characterization of Stem Cell Phenotype of Cancer Cells 
In order to investigate the expression patterns of CD44 and CD133 surface 
markers and stemness maintaining transcription factors SOX2 and NANOG, ICC was 






PC3 cells are human prostate cancer cells, and they do not express ID4 due to promoter 
methylation. PC3 (+) ID4 cells stably express ID4.15 
LNCaP (-)ID4 holoclones demonstrate increased expression of CD44 and CD133 
as compared to the LNCaP holoclones (Figure 17a). This indicates that LNCaP (-) ID4 
holoclone has more stemness. LNCaP (-)ID4  meroclones express less CD44 and CD133 
compared to LNCaP cells, although both meroclones express less stem cells markers 
compare to holoclones. Both LNCaP and LNCaP (-) ID4 paraclones do not express stem 
cells markers. This result indicates that paraclones do not have stemness (Figure 17 a). 
LNCaP (-) ID4 cells demonstrate more stemness.  This is further confirmed by ICC 
results on stemness maintaining transcription factors, SOX2 and NANOG (Figure 17 b). 
Western blot results on CD44 and CD133 in LNCaP and LNCaP (-) ID4 cells 
demonstrate LNCaP (-) ID4 has more stemness. Also LNCaP (-) ID4 cells express more 
stemness maintaining transcription factors SOX2 and NANOG (Figure 17c). 
DU145 holoclones demonstrate significantly higher expression levels of cell-
specific surface markers (CD44 and CD133) as compared to the paraclones (Figure 18 a). 
Also DU145 cells express more SOX2 and NANOG compared to DU145 (+) ID4 cells 
(Figure 18 b). Western blot results on CD44 and CD133 in DU145 and DU145 (+) ID4 
cells demonstrate DU145 has more stemness. Also DU145 cells express more stemness 
maintaining transcription factor SOX2 and NANOG (Figure 18c). Above results 







Figure 17. a)  ICC analysis of LNCaP and LNCaP (-) ID4 Holoclone, Meroclone, 
Paraclone expression of CD133 and CD44. b) ICC analysis of LNCaP and LNCaP (-) ID4 
expression of SOX2 and NANOG. c) Westernblot of CD133, CD44, and NANOG in LNCaP and 











Figure 18. a) ICC analysis of DU145 and DU145(+)ID4 Holoclone, and Paraclone 
expression of CD133 and CD44. b) ICC analysis of DU145 and DU145(+)ID4 expression of 
SOX2 and NANOG. c) Westernblot of CD133, CD44, SOX2 and NANOG in DU145 and 









Figure 19. a) ICC Analysis of PC3 and PC3(+)ID4 Holoclone, and Meroclone expression of 
CD133 and CD44.  
 
PC3 holoclone cells which are not express ID4 have more stem cell marker 
expression than PC3 (+) ID4 holoclones. Also, PC3 meraclone has less expression of 
CD44 and CD133, whereas PC3+ID4 do not express these stem cell markers. Above 
result further implicate that holoclones which do not express ID4 has more stemness 





4.6 FACS Analysis for Stem Cells 
Based on cancer stem cell surface marker CD133, cells were sorted out using 
FACS. FACS analysis data indicate that LNCaP (-) ID4 cells have more stem cells that is 
1.6% of the total cell population. This amount is fourfold higher than documented 









Figure 20. FACS Analysis Based on CD133 Surface Marker. 
 
  Sorted cells using FACS, showed that both LNCaP and LNCaP(-)ID4 cells 
express CD133 equally. Lower CD133 (+) LNCaP cells express ID4 (Figure 21), but 
sorted out LNCaP cells, which are believed to be cancer stem cells, do not express ID4. 






Figure 21. ICC of FACS Sorted Cell with CD133 and ID4. 
 
4.7 In vivo Tumor Formation  
10,000 LNCaP cells sorted out based on CD133 surface marker from FACS, were 
inoculated on left side flank on 3 SCID mice and 10,000 LNCaP cells from CD133 
negative were inoculated on the left side flank of another set of 3 SCID mice. CD133 




CD133 negative xenograft never developed a tumor. Fisher’s test on the tumor incidence 






Figure 22. A) Left 3 mice xenograft with CD133 positive LNCaP cells and right 2 mice 
xenograft with CD133 negative LNCaP cells. B) Tumors of CD133 positive xenograft. 
 
4.8 IHC on Xenograft 
IHC analysis of CD133 positive LNCaP xenograft does not show ID4 expression, 
although they are LNCaP cells. Figure 23 A is H&E staining of LNCaP xenograft tumor. 
Xenograft tissue does not express ID4 on IHC results (Figure 23 B). Figure 23 C and D 




expression on xenograft. These results indicate that CD133 positive LNCaP cells readily 
forms tumors and still behave as stem cells in the xenografts. 
 
Figure 23. A- H&E staining of LNCaP stemcell xenograft, B,C, D, E, F,G - IHC on  




























Figure 24.  a) Microarray data on PRMT1, and SOX2  b) FOXO1 histology. c) Relative 
expression of PRMT1, FOXO1 and SOX2 in LNCaP and DU145 cell lines. 
 
Tissue microarray IHC was performed on prostate cancer microarray slide T195b 
c147 on PRMT1, SOX2, and FOXO1. In normal prostate tissue PRMT1 and FOXO1 are 
expressed in physiological level. Increased expression of PRMT1 can be seen in prostate 
cancer which further increases with advancement of the cancer from stage 1 to stage 4 
(Figure 24 a). FOXO1 expression also increased in prostate cancer with nuclear 
localization (Figure 23 b). SOX2 expression is very minimal in normal prostate and its 
expression is increased in advanced prostate cancer (Figure 23 a). Q-PCR result on 
LNCaP, which express ID4, and DU145, which does not express ID4, cell lines 
demonstrate a similar result of the tissue microarray data:  relative PRMT1 expression is 
higher in DU145 cells compared to LNCaP cells. FOXO1 expression is similar in both 
DU145 and LNCaP cells. SOX2 is higher in DU145 cells compared to LNCaP cells 
(Figure 23 c). FOXO1 activity is changed based on its nuclear or cytoplasmic 
localization. Similar expression of FOXO1 in LNCaP and DU145 cells might have 






4.10 Molecular Mechanism Pathway 
Based on ID4, FOXO1, PRMT1 and AR expression and function in cancer stem 
cells in in our studies, I suggest a molecular mechanism model that maintains cancer stem 
cells (Figure 25). It is proposed that FOXO1 may play a major role in developing cancer 
and progression, while maintaining stemness. Although FOXO1 expression levels are not 
altered, its phosphorylation and methylation play a major role in the occurrence of 
prostate cancer and maintaining cancer stemness. PRMT1 expression keeps FOXO1 
methylated and retains its action in the nucleus.19 Our data demonstrate that PRMT1 is 
expressed at higher levels in prostate cancer with lower expression of ID4. PRMT1 
methylates proline on histones in chromatin. Here we hypothesized that PRMT1 
methylates histone on ID4 gene promoter regulating histone and prevents its transcription 
resulting in reciprocal expression of ID4 and PRMT1. It is well known that ID4 acts as 
tumor suppressor.  Our results suggest that in physiological conditions FOXO1 interacts 
with ID4 and regulate AR transcription as a complex. However, in cancer, either FOXO1 
/ID4 complex is detached or not formed due to lack of ID4 on AR and allowing AR to 
behave as a tumor promoter. On the other hand, once FOXO1 gets methylated, FOXO1 
can act itself acts as a transcription factor that can maintain cancer stemness. 
Although many in vitro studies have been performed on ID4 molecule and its role 
in prostate cancer, no acceptable molecular mechanism has emerged to address the 




Therefore, it is important to have an ideal mouse model with prostate specific ID4 
knockout, which mimic the real cancer occurrence sequence in human prostate cancer 
 
 
Figure 25. As ID4 play major role in maintaining normal cellular faction with other co regulation 
proteins, once it expression is absence or less due to histone methylation prostate cancer initiate 
and lack of ID4 also do not complex with FOXO1 and initiate its action on stemness maintaining 
transcription factors. 
 
Based on above molecular mechanisms, to identify the FOXO1, AR and ID4 
interactions, an immunoprecipitation (IP) study was performed on LNCaP and LNCaP(-
)ID4 cell lines. IP on AR and western blotting on FOXO1 clearly demonstrate that there 
is an interaction between AR and FOXO1 in LNCaP cell line (Figure26 A). Also, IP on 
FOXO1 and western blotting on AR demonstrate the similar results indicating that ID4 is 
important to make a complex between AR, and FOXO1. 
Nuclear Cytoplasmic extraction and western blot analysis of LNCaP and LNcaP(-
)ID4 on FOXO1 show more nuclear expression in LNCaP(-)ID4 cell lines, which is 
compatible with our hypothesis. When both cell lines were treated with PRMT1 




cytoplasmic export which can be explained by our hypothesis (Figure 26 B). Also, 
FOXO1 in cytoplasm indicates that there is increased phosphorylation and cytoplasmic 
export with PRMT1 inhibitors. Figure 26 C indicates relative FOXO1 expression in 
LNCaP and DU145 cells. Their relative expression is similar, but their FOXO1 
localization in nucleus and cytoplasm is different. 
In DU145 cells ID4 is not expressed because of epigenetic promotor suppression 
(Histone or DNA methylation or acetylation). DU145 cells were treated with PRMT1 and 
EZH2 inhibitors.  Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-
methyltransferase enzyme encoded by EZH2 gene, that participates in histone 
methylation and, ultimately, transcriptional repression. Nuclear cytoplasmic extraction 
and western blot showed emergence of ID4 expression following PRMT1 inhibitor-
treated DU145 cells. Although ID4 was also re-expressed with EZH2 inhibitor, this 







Figure 26. A) IP of AR and FOXO1 with western blot of FOXO1 and AR respectively. 
B) FOXO1 expression in LNCaP and LNCaP-ID4 cell with PRMT1 inhibitors. C)  Q-PCR 












Figure 27. A) Nuclear and Cytoplasmic Expression of ID4, and FOXO1 in DU145 cell with 
PRMT1 inhibitors and EZH2 inhibitors. B and C) PCR results of ID4 expression on DU145 cell 







 Loss of ID4 Promotes Prostate Cancer Stemness 
The aim of this study was to test the hypothesis that knockdown of ID4 
promotes prostate cancer stemness with a gene signature that resembles stem cells. The 
specific aims investigated whether ID4 selectively regulates the colony and sphere 
formation ability in prostate cancer cells.  Furthermore, we sought to investigate ID4 
dependent molecular mechanisms involved in the regulation of prostate cancer 
stemness. 
John Dick and co-workers showed that leukemic stem cells which are CD43+ 
and CD38-, can be transplanted to SCID mice in linear passages and develop leukemia. 
Also, they have shown that these cells have the colony formation ability.107 In 2003 Ul 
Hajj and co-workers did a similar experiment on solid tumor (Breast) to demonstrate 
the existence of cancer stem cells.108 Also, a cancer stem cell study on DU145 cells 
have showed that just 10,000 cancers stem cell are enough for the development of 
prostate cancer in xenograft within 40 days.47 Prostate cancer stem cells were first 
identified by Collins et al. (2005). Their studies showed that CD44+α2β1hiCD133+ 
cells isolated from prostate cancer patients have a high potential for self-renewal and 
proliferation; these cells were also able to differentiate to heterogeneous cancer cells in 
ex vivo culture (Collins et al., 2005). Since CSCs are conceptually considered to share 





to adapt knowledge from normal stem cell studies to explain CSC regulation 
mechanisms, so they believed that tumors contained a hierarchy of cells headed by 
cancer stem cells which can self-renew and differentiate to different stages cell types in 
cancer (heterogeneity).109 
The origin of CSCs is still controversial. Experimental evidence shows CSCs 
could originate from normal stem cells because CSCs share similar cell surface 
markers with normal stem cells. For example, in prostate, epithelial stem cells located 
in the basal layer of prostate gland have cell surface markers such as CD44, α2β1, and 
CD133.109 Surprisingly, the CD44+α2β1hiCD133+ prostate cancer cells have been 
shown to be PCSCs.109It seems that during carcinogenesis, normal prostate stem cells 
gain mutations in oncogenes and tumor suppressor genes that drive them to become 
PCSCs which is shown in our microarray data in figure 8. 
Prostatosphere and colony formation are classic microscopic morphological 
features to identify stem cells and cancer stem cells. In this study, loss of ID4 
demonstrates formation of more regenerative colonies (holoclones) and prostatosphere. 
Regenerative colonies (holoclones) have the ability to develop colonies for many 
generations, and this result further confirms its stemness. Characterization of 
regenerative colonies (holoclones) demonstrates expression of CD133 and CD44 
surface markers that are recognized surface marker for stem cells. Different cell 
specific activity such as ATP-binding cassette transport protein, analysis of ALDH 





CD133 surface marker to sort out 1.6% of total population of LNCaP (-) ID4 cells. 
Also 0.6% of stem cells from LNCaP do not express ID4. 
According to literature, 0.1% cell in a prostate cancer cell population maintains 
prostate cancer stemness at any given time.  These stem cells are resistant to 
chemotherapy and are considered castration resistant.24 This  may explain the 
recurrence of prostate cancer after treatment with castration, antiandrogen, 
chemotherapy or radiotherapy.110 Based on our results, it is evident that loss of ID4 can 
maintain the prostate cancer stemness.  
In stem cell maintaining pathway different transcription regulatory mechanism 
will activate to keep their stemness and sometime they reprogram or transactivate stem 
cell regulatory pathways. OCT4, NANOG, and SOX2 transcription factors play major 
role in maintaining stemness.27 SOX2 heterodimerize with OCT4 and regulate several 
genes demonstrating autologous feedback and control reciprocal transcription in a 
regulatory circuit.111 Apart from above transcription factors, many other factors 
(proteins) like sall4, Dax1, Tbx3 also play a role in maintaining stemness,112 via 
protein-protein interaction. Many of the genes are targets of NANOG and OCT4, 
indicating that the transcription network might have a feedback mechanism. Although 
above genes are responsible to maintain stemness, FOXO1 play a major role by 
methylating its arginine to activate itself as transcription factor for SOX2.  
Tissue microarray data suggests that ID4 is not expressed in prostate cancer and 





studies suggested that in breast and prostate cancers, PRMTs play a major role to 
methylate histone in promotor region and regulate cancer promoting and suppressing 
genes like ID4 and FOXO1.94, 113  PRMT1 which is expressed 90% of all cells has the 
ability to asymmetrically demethylate Histone 4 Arginine 3 (H4R3) in promotor region 
of genes and increase hydrophobicity that prevents transcription. According to our 
results, PRMT1 methylates H4R3 in ID4 promotor and prevents its tumor suppressor 
activity. Also PRMT1 methylates FOXO1 and prevents it from getting phosphorylated 
and subsequent cytoplasmic export.114  DU145 cells, which do not express ID4 due to 
epigenetic regulation, express ID4 with PRMT1 inhibition indicating that PRMT1 has 
an effect on ID4 promoter by methylation on its proline. We have to confirm this by 
further investigations on chromatin histone methylation on ID4 promoter.  
Prostate Development and Initiation of Prostate Cancer 
Different knockout mouse models have been studied to investigate the prostate 
development, cancer initiation and progression. There are few developmental details on 
Nkx3.1 and Pten knockout mouse models to have insight on prostate development and 
initiation of prostate cancer. 
Id4 knockout mice model study supports a role for Id4 as a key regulator of male 
genital tract development. Although we focused on the prostate, the size and 
development of accessory sex glands (seminal vesicles) and testis are also severely 
impaired.31 Id4 may not be required to maintain fertility, but it could cooperate with 





organs within the genital tract. Genital tract development in general and prostate in 
particular are androgen dependent. Prostate fetal development and structural and 
functional maturation at puberty are strictly androgen regulated.31 
Id4-/- mice display reduced ductal branching morphogenesis, epithelial 
hyperplasia, and dysplasia. According to previous study Nkx3.1 also regulate the 
prostate development and normal differentiation of the prostate epithelium with 40% less 
branching morphology observed in Id4-/-. Although Id4-/- shows attenuation of prostate 
development, Nkx3.1 -/- does not show any prostate size reduction.115 
Nevertheless, loss of Nkx3.1, a marker of epithelial differentiation and androgen 
response is a significant observation that further supports the attenuation of androgen 
regulatory network post androgen receptor expression in the Id4-/- prostates. Nkx3.1 also 
regulates the rate at which proliferating luminal epithelial cells exit the cell cycle, and its 
loss extends the transient proliferative phase of luminal cells which is consistent with 
increased expression of ki67in Id4-/- prostate. 
Observed in Id4-/- mice could also promote Myc dependent transactivation of 
pro-tumorigenic target genes. Mice expressing Myc in the prostate also develop PIN like 
lesions followed by invasive adenocarcinoma.116 Myc has an effect on activation of 
micRNA21 which has transcription interference for many proteins. MicRNA21 also has 
interference effect on Pten will initiate prostate carcinoma, which has been shown by 





Alpha-methylacyl-CoA racemase (AMACR) is strongly expressed in prostate 
cancer with variable expression in high-grade prostatic intraepithelial neoplasia (HGPIN) 
and low expression in normal prostate. In Id4-/-, high AMACR expression indicate that 
the presence of pre-PIN lesions, a significant observation. Why these cells do not 
demonstrate extensive PIN lesions remains to be investigated.  We believe that with 
progressive age we may observe increased PIN lesions with significant penetration. 
Although Id4-/- mice do not develop full-blown prostate carcinoma like in Pten -
/- mice, its alteration of tumor promoting genes suggest that it has the potential to 
generate prostate carcinoma. Sca-1 indicates there is a defect in epithelial differentiation 
into tubule by retaining their stemness. The defect in differentiation below a certain 










The Id4-/- knockout presents a complex prostate phenotype. Loss of Id4 results in 
altered prostate development but also leads to or promotes some PIN like lesions with 
maintaining its stem cells, that are supported both by morphological and specific marker 
studies.  
In vivo studies on different prostate cancer cell lines, with stable ID4 knockdown 
demonstrated that loss of Id4 can selectively increase the colony and sphere formation 
ability in prostate cancer with expression of cell specific surface markers that are widely 
expressed in prostate cancer stem cells. 
As ID4 is epigenetically silenced in prostate cancer, our result may explain that 
PRMT1 high expression involved in histone methylation to prevent expression of ID4. 





co-chaperon to make complex with AR to regulate normal metabolism of the cellular 
level, is altered with arginine methylation by PRM1, and can changes its 
compartmentation and involvement in the maintaining of prostate cancer stemness. 
Treatment with PRMT1 inhibitors on ID4 non expressing cells regains ID4 expression 
with suppression of stemness maintaining transcription factors like SOX2. This ID4 and 
its relationship with PRMT in maintaining cancer stem cells will be promising steps to 
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